|
WO2011156000A2
|
|
Use of il-4/il-13 antagonists to treat eosinophilic disorders
|
|
WO2011106779A1
|
|
Use of modified il-4 mutien receptor antagonists to treat dermatitis
|
|
WO2010105227A1
|
|
Methods of renaturation of recombinant proteins
|
|
BRPI0814696A2
|
|
polypeptide dry powder aerosol pharmaceutical formulation and preparation method
|
|
AU2008274938A1
|
|
Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
|
|
US2009010874A1
|
|
Modified IL-4 mutein receptor antagonists
|
|
US2007212308A1
|
|
Methods for treating asthma in human and non human primates using IL-4 mutant compositions
|
|
CN101426518A
|
|
Methods and compositions for treating asthma in human and non human primates
|
|
ZA200702529B
|
|
Interleuk-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
US2007009479A1
|
|
Methods for treating dermatitis using mutant human IL-4 compositions
|
|
WO2006002064A2
|
|
Antibody inhibiting stem cell factor activity and use for treatment of asthma
|
|
US2006063236A1
|
|
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
CN1871254A
|
|
The IL-4 mutein receptor antagonists of modifying
|
|
NZ574252A
|
|
Modified IL-4 mutein receptor antagonists
|
|
US7423123B2
|
|
Interleukin-9 antagonist muteins and their pharmacological methods of use
|
|
US2005059590A1
|
|
Modified IL-4 mutein receptor antagonists
|
